Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non–small cell lung cancer
暂无分享,去创建一个
Y. Oda | Hidetaka Yamamoto | I. Okamoto | Kentaro Tanaka | Kayo Ijichi | Y. Yoneshima | E. Iwama | R. Ibusuki | Fumihiko Okubo | Yoshimasa Shiaraishi
[1] K. Okudela,et al. Pathological criteria for multiplex gene-panel testing using next-generation sequencing in non-small cell lung cancer. , 2022, Cancer treatment and research communications.
[2] Kentaro Fujiwara,et al. Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non‐small cell lung cancer , 2022, Thoracic cancer.
[3] H. Yoshida,et al. Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L , 2021, Cancer science.
[4] A. Ochiai,et al. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine , 2021, Pathology international.
[5] M. Nishio,et al. Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice , 2020, Thoracic cancer.
[6] M. Masuda,et al. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples , 2020, Thoracic cancer.
[7] J. Desai,et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. , 2020, The New England journal of medicine.
[8] H. Groen,et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.
[9] A. Drilon,et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.
[10] Jie Yang,et al. Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06 , 2018, The New England journal of medicine.
[11] J. Subramanian,et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform , 2018, PloS one.
[12] Ying Cheng,et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .
[13] Young Hak Kim,et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.
[14] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[15] J. Yokota,et al. Gene aberrations for precision medicine against lung adenocarcinoma , 2016, Cancer science.
[16] Ariel Birnbaum,et al. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. , 2016, Journal of oncology practice.
[17] R. Goswami,et al. Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies , 2015, Cancers.
[18] Rakesh Nagarajan,et al. Clinical next‐generation sequencing in patients with non–small cell lung cancer , 2015, Cancer.
[19] K. Arnaoutakis. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2015, The New England journal of medicine.
[20] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[21] Stefan M Willems,et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate , 2014, Modern Pathology.
[22] David L Rimm,et al. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. , 2013, Archives of pathology & laboratory medicine.
[23] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[24] Yi-long Wu,et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[26] C. Morrison,et al. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single‐gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non–Small‐cell Lung Cancer: A Single‐center Analysis , 2019, Clinical lung cancer.
[27] T. Miyazaki,et al. Brief Report: Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] H. Groen,et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.